Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2024-07-02 00:00:00 ET · period of report 2024-07-01 · accession 0000914475-24-000166 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-07-02 | 2024-07-01 | NBIX | Cooke Julie | CHRO | S - Sale+OE | $140.19 | -10.0K | 18.2K | -35% | -$1.40M |
| D | 2024-07-02 | 2024-07-01 | NBIX | Cooke Julie | CHRO | M - OptEx | $61.82 | +10.0K | 28.2K | +55% | +$618.2K |
| D | 2024-07-02 | 2024-07-01 | NBIX | Cooke Julie | CHRO | M - OptEx | $0.00 | -10.0K | 13.5K | -42% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-01 | S | D | 10,000 | $140.19 | 18,202 | D | — | — | (F3) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.48. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F4) 16,538 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. |
| 2 | Common | Common Stock | 2024-07-01 | M | A | 10,000 | $61.82 | 28,202 | D | — | — | (F1) Includes an aggregate of 226 shares purchased on February 29, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 3 | Derivative | Non-Qualified Stock Option | 2024-07-01 | M | D | 10,000 | $0.00 | 13,532 | D | $61.82 · — to 2027-10-02 | 10,000 Common Stock | (F5) Represents option of which 1/4th of the shares underlying the option became vested and exercisable on October 2, 2018 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter. These options will expire ten years from the date of grant on October 2, 2027. |